Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma

Saurabh Agarwal; Giorgio Milazzo; Kimal Rajapakshe; Ronald Bernardi; Zaowen Chen; Barbieri Eveline; Jan Koster; Giovanni Perini; Cristian Coarfa; Jason M. Shohet

doi:10.18632/oncotarget.25776

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma

PDF | How to cite

Oncotarget. 2018; 9:30024-30024. https://doi.org/10.18632/oncotarget.25776

Metrics: PDF 1863 views | ?

Saurabh Agarwal^1,*, Giorgio Milazzo^2,*, Kimal Rajapakshe^3,*, Ronald Bernardi¹, Zaowen Chen¹, Barbieri Eveline¹, Jan Koster⁴, Giovanni Perini^2,**, Cristian Coarfa^3,** and Jason M. Shohet^1,**

¹Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
²Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
³Dan L Duncan Cancer Center, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA
⁴Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
^*These authors are considered as co-first authors
^**These authors are considered as co-last authors

Published: July 06, 2018

This article has been corrected: The corrected author name is given below:

Barbieri Eveline

Original article: Oncotarget. 2018; 9:20323-20338. DOI: https://doi.org/10.18632/oncotarget.24859.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25776

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma